#ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination

#ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination

307724

#ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination

An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging data measuring the magnetization transfer ratio (MTR) also suggest gains in these ATA188-treated patients may be tied to remyelination, or the regrowth of the myelin sheath, the fatty…

You must be logged in to read/download the full post.